Serum discrimination of early-stage lung cancer patients using electrospray-ionization mass spectrometry

Lung Cancer

Volumn 74, Issue 2, 2011, Pages 206-211

  Hocker, James R ^a   Peyton, Marvin D ^b   Lerner, Megan R ^b,c   Mitchell, Stephanie L ^b,c   Lightfoot, Stan A ^c   Lander, Theresa J ^b,c   Bates Albers, Leah M ^a   Vu, Nicole T ^d   Hanas, Rushie J ^a   Kupiec, Thomas C ^d   Brackett, Daniel J ^b,c   Hanas, Jay S ^a,b,c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Analytical Research Laboratories   (United States)

Author keywords

Early detection; Electrospray ionization; Lung cancer; Mass spectrometry; Non small cell lung carcinoma; Serum profiling

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; EARLY CANCER; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; LUNG CANCER; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSIS, DIFFERENTIAL; EARLY DETECTION OF CANCER; FEASIBILITY STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 80053636773     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.03.014     Document Type: Article

References (25)

1. American Cancer Society Cancer facts & figures 2009, American Cancer Society, Inc., Atlanta (GA), http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_ Facts__Figures_2009.asp?from=fast.
2. Greenberg A.K., Lee M.S. Biomarkers for lung cancer: clinical uses. Curr Opin Pulm Med 2007, 13:249-255.
3. Okada M., Nishio W., Sakamoto T., Uchino K., Yuki T., Nakagawa A., et al. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease. Ann Thorac Surg 2004, 78:216-221.
4. Howard B.A., Zheng Z., Campa M.J., Wang M.Z., Sharma A., Haura E., et al. Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer 2004, 46:313-323.
5. Yang S.Y., Xiao X.Y., Zhang W.G., Zhang L.J., Zhang W., Zhou B., et al. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 2005, 1-7. 5 83.
6. Poli D., Carbognani P., Corradi M., Goldoni M., Acampa O., Balbi B., et al. Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respir Res 2005, 6(71):1-10.
7. Richter R., Schuz-Knappe P., Schrader M., Standker L., Jurgens M., Tammen H., et al. Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J Chrom B: Biomed Sci Appl 1999, 726:25-35.
8. Chambers G., Lawrie L., Cash P., Murray G.L. Proteomics: a new approach to the study of disease. J Pathol 2000, 192:280-288.
9. Verma M., Wright G.L., Hanash S.M., Gopal-Srivastava R., Srivastava S. Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Ann NY Acad Sci 2001, 945:103-115.
10. Hanas J.S., Hocker J.R., Cheung J.Y., Larabee J.L., Lerner M.R., Lightfoot S.A., et al. Biomarker identification in human pancreatic cancer sera. Pancreas 2008, 36:61-69. 2008.
11. Semmes O.J., Feng Z., Adam B.L., Banez L.L., Bigbee W.L., Campos D., et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I assessment of platform reproducibility. Clin Chem 2005, 51:102-112.
12. Hortin G.L. Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice?. Clin Chem 2005, 51:3-5.
13. West-Nørager M., Bro R., Marini F., Høgdall E.V., Høgdall C.K., Nedergaard L., et al. Feasibility of serodiagnosis of ovarian cancer by mass spectrometry. Anal Chem 2009, 81:1907-1913.
14. Villanueva J., Shaffer D.R., Philip J., Chaparro C.A., Erdjument-Bromage H., Olshen A.B., et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006, 116:271-284.
15. Sorace J.M., Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinform 2003, 4:24.
16. Li J., Zhang Z., Rosenzweig J., Wang Y.Y., Chan D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002, 48:1296-1304.
17. Hocker J.R., Lerner M.R., Mitchell S.L., Lightfoot S.A., Lander T.J., Quillet A., et al. Distinguishing early clinical stages of pancreatic cancer using serum profiling. Cancer Invest 2011, 29:173-179.
18. Sobin L.H., Wittekind C. International Union against cancer; TNM: classification of malignant tumors 2002, Wiley-Liss, New York, NY. 6th ed.
19. Guan W., Zhou M., Hampton C.Y., Benigno B.B., Walker L.D., Gray A., et al. Ovarian cancer detection from metabolomic liquid chromatography/mass spectrometry data by support vector machines. BMC Bioinform 2009, 10:259-274.
20. Ransohoff D.F. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004, 4:309-314.
21. Altman D.G., Bland M. Statistics notes: diagnostic tests 2: predictive values. Brit Med J 1994, 309:102.
22. Altman D.G., Bland M. Statistics notes: diagnostic tests 1: sensitivity and specificity. Brit Med J 1994, 308:1552.
23. National Committee for Clinical Laboratory Standards. User evaluation of precision performance of clinical chemistry devices. NCCLS Tentative Guideline EP5-T 2004.
24. Postier R.G., Lerner M.R., Lightfoot S.A., Vannarath R., Lane M.M., Hanas J.S., et al. DNA ploidy and markovian analysis of neoplastic progression in experimental pancreatic cancer. J Histochem Cytochem 2003, 51:303-309.
25. Larabee J.L., Hocker J.R., Cheung J.Y., Gallucci R.M., Hanas J.S. Serum profiling of rat dermal exposure to JP-8 fuel reveals an acute-phase response. Toxicol Mech Meth 2008, 18:41-51.